Immuneering | 8-K: Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates -Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in

Immuneering | 8-K：Immuneering公佈2023年第三季度財務業績並提供業務更新——IMM-1-104 1/2a期試驗的劑量評估部分約有三分之二入組；Immuneering建議的2期劑量預計在2024年初接種-